ASX-LISTED medical dermatology company Botanix Pharmaceuticals has announced the appointment of two highly qualified global pharmaceutical industry executives to expand the company's clinical development capabilities.
Dr Stephane Levy has taken up the role of chief medical officer and Jillian Chapas-Reed is senior director of Clinical Operations.
Their appointments bring significant clinical expertise in acne, dermatitis and psoriasis and extensive late stage clinical development experience to Botanix, helping accellerate the BTX 1503 acne and BTX 1204 atopic dermatitis Phase 2 clinical trials.
Both Phase 2 clinical trials are fully funded, the company said in its ASX announcement (PD 28 Jun).
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jul 18
